Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||7-hydroxystaurosporine + Sirolimus|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|7-hydroxystaurosporine||UCN-01|KRX-0601|NSC-638850||CDK Inhibitor (Pan) 4 CHK1 Inhibitor 15 PKC alpha Inhibitor 6 PKC beta Inhibitor 6 PKC Inhibitor (Pan) 10||7-hydroxystaurosporine (UCN-01) is a derivative of staurosporine that inhibits CHK1 and PKC, with higher potency toward PKC-alpha, PKC-beta, and PKC-gamma, and also modulates CDK activity through upregulation of CDK inhibitors, potentially resulting in inhibition of tumor growth (PMID: 8022414, PMID: 15831461, PMID: 15150122, PMID: 31942030).|
|Sirolimus||Rapamune||Rapamycin||mTORC1 Inhibitor 8||Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||7-hydroxystaurosporine + Sirolimus||Preclinical||Actionable||In a preclinical study, Rapamune (sirolimus), in combination with UCN-01 (sc-3510), resulted in apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells in culture (PMID: 19223503).||19223503|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|